Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

UPTRAVI

SELEXIPAG

Standard Dose
1.8MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview UPTRAVI is listed in Drugs@FDA under application 214275 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SELEXIPAG Form and strength POWDER;INTRAVENOUS - 1.8MG/VIAL Sponsor ACTELION Submission history Latest submission status date: 2021-07-29 00:00:00.

Structured Monograph

Clinical summary

Approval overview UPTRAVI is listed in Drugs@FDA under application 214275 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SELEXIPAG Form and strength POWDER;INTRAVENOUS - 1.8MG/VIAL Sponsor ACTELION Submission history Latest submission status date: 2021-07-29 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.